Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
^NBI Performance Chart
NASDAQ Biotechnology Index (^NBI) is down 0.1% since the beginning of the year. ^NBI is currently trading at $5,701 per share. Investors who bought $1,000 worth of ^NBI shares 5 years ago would now be looking at an investment worth $1,202.
Loading charts...
Returns By Period
NASDAQ Biotechnology Index (^NBI) has returned -0.11% so far this year and 37.53% over the past 12 months. Over the last ten years, ^NBI has returned 6.82% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.
NASDAQ Biotechnology Index
- 1D
- -3.02%
- 1M
- -1.70%
- YTD
- -0.11%
- 6M
- 0.83%
- 1Y
- 37.53%
- 3Y*
- 11.13%
- 5Y*
- 3.74%
- 10Y*
- 6.82%
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
^NBI Monthly Returns History
Based on dividend-adjusted daily data since Nov 1, 1993, ^NBI's average daily return is +0.06%, while the average monthly return is +1.14%. At this rate, an investment would double in approximately 5.1 years.
Historically, 56% of months were positive and 44% were negative. The best month was Feb 2000 with a return of +45.3%, while the worst month was Mar 2000 at -25.8%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.
On a daily basis, ^NBI closed higher 52% of trading days. The best single day was Oct 13, 2008 with a return of +11.9%, while the worst single day was Mar 14, 2000 at -12.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.55% | 3.22% | -3.34% | 0.40% | 2.16% | -4.82% | -0.11% | ||||||
| 2025 | 5.15% | -0.32% | -6.06% | 0.38% | -4.26% | 3.64% | 5.52% | 4.85% | 4.32% | 9.97% | 8.41% | -1.90% | 32.40% |
| 2024 | 0.33% | 0.99% | 0.03% | -6.04% | 5.74% | 3.28% | 6.56% | 0.79% | -2.34% | -2.47% | -0.11% | -7.19% | -1.37% |
| 2023 | 3.50% | -6.55% | 1.23% | 1.50% | -2.73% | 0.10% | 1.30% | -0.37% | -3.91% | -6.56% | 4.87% | 12.82% | 3.74% |
| 2022 | -11.87% | -4.12% | 4.25% | -9.73% | -1.32% | 1.02% | 4.11% | -1.06% | -2.44% | 8.91% | 5.87% | -3.01% | -10.91% |
| 2021 | 6.25% | -2.37% | -4.29% | 2.97% | -2.03% | 8.00% | -0.20% | 4.09% | -4.91% | -1.89% | -3.95% | -1.31% | -0.63% |
Benchmark Metrics
NASDAQ Biotechnology Index has an annualized alpha of 3.91%, beta of 1.01, and R2 of 0.45 versus S&P 500 Index. Calculated based on daily prices since November 02, 1993.
- This index captured 107.17% of S&P 500 Index gains but only 98.39% of its losses - a favorable profile for investors.
- R2 of 0.45 means the benchmark explains less than half of this index's behavior - treat beta with caution or consider switching to a more representative benchmark.
- Alpha
- 3.91%
- Beta
- 1.01
- R²
- 0.45
- Upside Capture
- 107.17%
- Downside Capture
- 98.39%
Return for Risk
Risk / Return Rank
^NBI ranks 74 for risk / return — better than 74% of indices on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for NASDAQ Biotechnology Index (^NBI) and compare them to S&P 500 Index.
| ^NBI | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.91 | 2.39 | -0.48 |
Sortino ratioReturn per unit of downside risk | 2.70 | 3.25 | -0.55 |
Omega ratioGain probability vs. loss probability | 1.32 | 1.43 | -0.11 |
Calmar ratioReturn relative to maximum drawdown | 4.46 | 3.11 | +1.35 |
Martin ratioReturn relative to average drawdown | 14.78 | 14.38 | +0.39 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the NASDAQ Biotechnology Index. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the NASDAQ Biotechnology Index was 74.70%, occurring on Jul 10, 2002. Recovery took 2681 trading sessions.
The current NASDAQ Biotechnology Index drawdown is 7.03%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Dot-com crash2000–2002 | -74.70%Jul 2002 | 2y 4mo | 10y 8mo | 13y 1dMar 2000 - Mar 2013 |
2016 bear market2016 | -39.40%Jun 2016 | 11mo 12d | 3y 10mo | 4y 9moJul 2015 - May 2020 |
Bear market2022 | -38.50%Jun 2022 | 10mo 7d | 3y 5mo | 4y 3moAug 2021 - Nov 2025 |
1994 bear market1994 | -31.85%Apr 1994 | 2mo 18d | 1y 3mo | 1y 5moFeb 1994 - Jul 1995 |
1998 bear market1998 | -28.07%Aug 1998 | 10mo 21d | 2mo 5d | 1y 21dOct 1997 - Nov 1998 |
Drawdown Indicators
| ^NBI | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -74.70% | -56.78% | -17.92% |
Max Drawdown (1Y)Largest decline over 1 year | -8.45% | -9.10% | +0.65% |
Max Drawdown (3Y)Largest decline over 3 years | -24.08% | -18.90% | -5.18% |
Max Drawdown (5Y)Largest decline over 5 years | -38.50% | -25.43% | -13.07% |
Max Drawdown (10Y)Largest decline over 10 years | -38.50% | -33.92% | -4.58% |
Current DrawdownCurrent decline from peak | -7.03% | 0.00% | -7.03% |
Average DrawdownAverage peak-to-trough decline | -26.61% | -10.72% | -15.89% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.55% | 1.97% | +0.58% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Build a portfolio with ^NBI
Add NASDAQ Biotechnology Index to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ^NBI